Dr Reddys Laboratories shares fall 2.03%; stock among top losers on Nifty 50

Shares of Dr Reddys Laboratories declined 2.03% to Rs 1,271.70 on Thursday. The stock is among the top losers on the Nifty 50 index.

Financial Snapshot:

The following table summarizes the key consolidated financial figures for Dr Reddys Laboratories:

The company's revenue has shown a consistent increase over the quarters, from Rs 7,696.10 Crore in June 2024 to Rs 8,572.10 Crore in June 2025. Net profit also saw fluctuations, with a peak of Rs 1,581.20 Crore in March 2025. Earnings per share (EPS) varied across the quarters, with the highest value recorded in June 2024 at Rs 83.61.
The annual revenue for Dr Reddys Laboratories has steadily increased from Rs 19,047.50 Crore in 2021 to Rs 32,643.90 Crore in 2025. Similarly, the net profit has risen from Rs 1,903.60 Crore in 2021 to Rs 5,703.50 Crore in 2025. The EPS increased significantly from Rs 117.67 in 2021 to Rs 335.22 in 2024, before falling to Rs 67.89 in 2025. Book Value Per Share (BVPS) increased year-over-year until 2024, but saw a sharp decline in 2025. The company’s Return on Equity (ROE) and Debt to Equity ratio have remained relatively stable over the five-year period.

Income Statement:

The sales have increased year over year. The net profit for the company has also increased.

Quarterly Income Statement:

The sales for the company has increased over the past quarters. The net profit has increased in the quarter ending March 2025.

Cash Flow:

The company's cash flow from operating activities has varied over the years. Investing activities have consistently resulted in negative cash flow, while financing activities have fluctuated between positive and negative values.

Balance Sheet:

The company's reserves and surplus have increased steadily over the years. Total liabilities and total assets have also shown consistent growth.

Financial Ratios:

The basic and diluted EPS values have fluctuated over the past five years. The dividend per share has remained relatively consistent. The price-to-earnings (P/E) ratio and price-to-book (P/B) ratio have varied, reflecting changes in the company's valuation.

Corporate Actions

Dr Reddys Laboratories announced a final dividend of Rs 8.00 per share (800%) on May 9, 2025, with an effective date of July 10, 2025. The company had previously announced dividends of Rs 40.00 per share in 2024 and 2023. The stock split was announced on July 27, 2024 and exsplit date was on October 28, 2024 where old FV was 5 and new FV was 1.

Dr Reddys Laboratories is included as one of the stocks in the benchmark Nifty 50 index.

Moneycontrol analysis suggests a neutral sentiment on the stock as of September 25, 2025.